Evidence map›Paper›PMID 32518981›Full record

ArticleInflammopharmacology2020

Anti-inflammatory and anti-hyperalgesic effects of milnacipran in inflamed rats: involvement of myeloperoxidase activity, cytokines and oxidative/nitrosative stress.

Rasool Haddadi, Rojin Rashtiani

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Carrageenan-induced immunothrombotic models in rodents (Review).Experimental and therapeutic medicine · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Heliyon · 2021
    Article
  15. Efficacy ofMarine drugs · 2021
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rasool HaddadiDepartment of Pharmacology and Toxicology, Medicinal Plant and Natural Products Research Center, School of Pharmacy, Hamadan University of Medical Sciences, 6517838678, Hamadan, Iran. haddadi.rasool@gmail.com.ORCID http://orcid.org/0000-0001-9642-4665
Rojin RashtianiDepartment of Pharmacology and Toxicology, Medicinal Plant and Natural Products Research Center, School of Pharmacy, Hamadan University of Medical Sciences, 6517838678, Hamadan, Iran.
Hamedan University of Medical Sciences · IR

Funding

Hamadan University of Medical Sciences 9605103034
6 · The paper itself

Abstract

backgroundMany injuries cause pain and inflammation, which are one of the major challenges for physicians. In this study, the analgesic and the anti-inflammatory effects of milnacipran were investigated on carrageenan-induced nociception and inflammation in male rats.

methodsPain and inflammation were induced by injection of λ-carrageenan (1% v/v) into the hind paw. Indomethacin (10 mg/kg: ip) or milnacipran (10, 20 and 40 mg/kg: ip) were administered 30 min before carrageenan. Analgesia and inflammation were measured by hot plate and plethysmometer. Finally, lipid peroxidation, tumor necrosis factor alpha (TNF-α), Interleukin 1 beta (IL-1β), Interleukin 6 (IL-6), myeloperoxidase (MPO) activity, nitric oxide (NO) and total antioxidant capacity (TAC) status evaluated in the hind paw tissue.

resultsThe results showed that carrageenan caused hyperalgesia and inflammation in the hind paw tissue. Milnacipran (20 and 40 mg/kg) significantly and dose-dependently attenuated (65 ± 3.2%; p ≤0.01 and 42 ± 6.2%; p ≤ 0.001, respectively) carrageenan-induced inflammation and significantly increased (p ≤ 0.001) nociception threshold. Also, milnacipran (20 and 40 mg/kg) significantly suppressed levels of malondialdehyde (MDA), NO (p ≤ 0.05), MPO activity, TNF-α, IL-1β and IL-6 (p ≤ 0.001) following carrageenan injection. Additionally, milnacipran (10, 20 and 40 mg/kg) significantly augmented (p ≤ 0.05) TAC status following carrageenan in the hind paw tissue.

conclusionIn the present study, milnacipran showed anti-nociceptive and anti-inflammatory effects on carrageenan-induced hyperalgesia and inflammation in a dose-dependent manner. Milnacipran reduced inflammatory edema and increased the paw withdrawal threshold probably through suppression of MDA, NO, TNF-α, IL-1β, IL-6 and MPO activity, and increase of TAC status in the hind paw tissue. Therefore, milnacipran holds important potential as an anti-inflammatory and anti-nociceptive drug. Although, further clinical trials to confirm this issue, is required.

Indexed as

AnalgesicsAnimalsAnti-Inflammatory AgentsCarrageenanCytokinesDisease Models, AnimalEdemaHyperalgesiaIndomethacinInflammationInterleukin-1betaInterleukin-6MaleMalondialdehydeMilnacipranNitric OxideAnalgesicsAnti-Inflammatory AgentsCarrageenanCytokinesIndomethacinInterleukin-1betaInterleukin-6MalondialdehydeMilnacipranNitric OxidePeroxidaseTumor Necrosis Factor-alphaCarrageenanInflammatory cytokinesMalondialdehydeMilnacipranMyeloperoxidasePain and analgesiaPlethysmometerRat

Identifiers

PMID32518981
OpenAlexW3033272031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.